At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-center Randomized, Double-blind, Placebo Controlled, Parallel-group Study of CD07743 for the Improvement of Lateral Canthal Lines (Crow's Feet)
In Brief
A Phase 3 clinical trial evaluating Botulinum Toxin Type A and Placebo for Canthal Lines. Completed, enrolled 335 participants.
Detailed Summary
This double-blind study has two parts for each subject (same population): Part A: initial treatment in Lateral Canthal Lines (LCL) (placebo-controlled): * To assess the efficacy and safety of Azzalure® compared to placebo in the improvement of moderate to severe LCLs. * To assess the subjects' level of satisfaction with the appearance of their LCLs compared to placebo. Part B: repeated treatment in LCL with or without Glabellar Lines (GL) (active treatment, up to 1 year): * To assess safety of Azzalure® following repeated administration in the improvement of moderate to severe LCLs. * To assess the safety of Azzalure® when used concomitantly for improvement of moderate to severe LCLs and GLs. * To assess the subjects' level of satisfaction with the appearance of their LCLs.
Study Details
Timeline
Interventions
During part A, Azzalure will be administered at Baseline 60 Speywood units at canthal lines and compared with placebo.